Fundraising Fox

/Companies

Delcath Systems

NASDAQ: DCTH

Ny, US · Founded 1987 · Delaware corporation · 151 employees on LinkedIn · 1 known investors

Find your way into Delcath Systems

Sign up to see every warm intro you have to Delcath Systems

Paths you didn't know you had: your email and LinkedIn already hold routes to the Delcath Systems team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Delcath Systems is a commercial-stage interventional oncology company developing minimally-invasive treatments for patients with primary and metastatic liver cancers. Its FDA-approved therapy targets adult patients with metastatic uveal melanoma, marketed in the US and Europe.

Biotech Healthtech Medical Devices

Founders & leadership

BK

Barbra KeckChief Financial Officer2017–2020

JS

Jennifer SimpsonPresident and CEO2015–2020

GM

Gerard Michel Chief Executive Officer

MT

Marco TagliettiNamed on SEC filing

Board

RS

Roger StollBoard director

WR

William RueckertBoard director

Investors · 1

Altium CapitalreportedNew York

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$71.9M disclosed across 7 of 8 rounds · 1900–2024

▶$7MraisedMar 2024 · 17 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven SalamonDirector
Elizabeth CzerepakDirector
Vojo VukovicExecutive Officer
Gerard MichelExecutive Officer, Director
Gilad AharonDirector
Roger G. StollDirector
Martha RookExecutive Officer
David J. HoffmanExecutive Officer
Kevin MuirExecutive Officer
John R. SylvesterDirector
Sandra PennellExecutive Officer

Offering amount: $7M
Amount sold: $7M
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25MraisedMar 2023 · 17 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Gerard MichelExecutive Officer, Director
Kevin MuirExecutive Officer
Anthony DiasExecutive Officer
John PurpuraExecutive Officer
Elizabeth CzerepakDirector
Gilad AharonDirector
Johnny JohnExecutive Officer
Steven SalamonDirector
David HoffmanExecutive Officer
Roger G. StollDirector
John R. SylvesterDirector

Offering amount: $25M
Amount sold: $25M
Sales commissions: $1.5M
Placement agents: Canaccord Genuity LLC, Roth Capital Partners, LLC, BTIG, LLC
First sale: Mar 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.8MraisedDec 2022 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kevin MuirExecutive Officer
Gilad AharonDirector
David HoffmanExecutive Officer
John R. SylvesterDirector
Roger G. StollDirector
Anthony DiasExecutive Officer
Gerard MichelExecutive Officer, Director
Johnny JohnExecutive Officer
Steven SalamonDirector
John PurpuraExecutive Officer
Elizabeth CzerepakDirector

Offering amount: $3.8M
Amount sold: $3.8M
First sale: Dec 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5MraisedJul 2022 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Johnny JohnExecutive Officer
Steven SalamonDirector
Gerard MichelExecutive Officer, Director
Gilad AharonDirector
John R. SylvesterDirector
Elizabeth CzerepakDirector
Roger G. StollDirector
Anthony DiasExecutive Officer
David HoffmanExecutive Officer
John PurpuraExecutive Officer
Kevin MuirExecutive Officer

Offering amount: $5M
Amount sold: $5M
First sale: Jul 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$9.5MraisedAug 2019 · 33 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John R SylvesterDirector
Jennifer K SimpsonExecutive Officer, Director
Barbra C KeckExecutive Officer
John PurpuraExecutive Officer
William D RueckertDirector
Roger G StollDirector
Marco TagliettiDirector

Offering amount: $9.5M
Amount sold: $9.5M
Sales commissions: $738.3K
Placement agents: Roth Capital Partners, LLC
First sale: Aug 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$20MraisedJul 2019 · 31 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Marco TagliettiDirector
Roger G StollDirector
Jennifer K SimpsonExecutive Officer, Director
Barbra C KeckExecutive Officer
John PurpuraExecutive Officer
William D RueckertDirector

Offering amount: $20M
Amount sold: $20M
Sales commissions: $1.4M
Proceeds to insiders: $500K
Placement agents: Roth Capital Partners, LLC
First sale: Jul 2019
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.6MraisedAug 2018 · 1 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Roger StollDirector
Barbra KeckExecutive Officer
Jennifer SimpsonExecutive Officer, Director
William RueckertDirector
Marco TagliettiDirector

Offering amount: $1.6M
Amount sold: $1.6M
Minimum investment: $1M
Sales commissions: $208K
Placement agents: Roth Capital Partners, Advisory Group Equity Services Ltd.
First sale: Jul 2018
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Delcath Systems went on to found or lead other companies.

Laura PhilipsBoard of Directors, Chair Compensation CommitteeFounded Spheryx Samuel HerschkowitzChairman, Chief Operating Officer and Chief Technical OfficerFounded Serenity Pharmaceuticals

In the news

Delcath Systems to Attend 2 Investor Conferences | DCTH Stock Newsstocktitan.net · Aug 2026

Frequently asked questions

What does Delcath Systems do?: Delcath Systems is a commercial-stage interventional oncology company developing minimally-invasive treatments for patients with primary and metastatic liver cancers. Its FDA-approved therapy targets adult patients with metastatic uveal melanoma, marketed in the US and Europe.
Who are Delcath Systems's investors?: Delcath Systems's investors include Altium Capital.
How much funding has Delcath Systems raised?: Delcath Systems has disclosed $71.9M raised across 7 of its 8 known rounds.
Where is Delcath Systems headquartered?: Delcath Systems is headquartered in Ny, US.